|
May 18
|
Mirum Pharmaceuticals’ LIVMARLI Data Showcased at ESPGHAN Annual Meeting
|
|
May 13
|
Mirum Pharmaceuticals, Inc. (NASDAQ:MIRM) Q1 2024 Earnings Call Transcript
|
|
May 10
|
Mirum Pharmaceuticals Inc (MIRM) Q1 2024 Earnings: Misses Revenue Forecasts, Posts Wider Net Loss
|
|
May 9
|
Mirum's (MIRM) Q1 Earnings & Revenues Fall Shy of Estimates
|
|
May 9
|
Q1 2024 Mirum Pharmaceuticals Inc Earnings Call
|
|
May 9
|
Mirum Pharmaceuticals Inc (MIRM) Q1 2024 Earnings Call Transcript Highlights: Soaring Sales and ...
|
|
May 8
|
Mirum Pharmaceuticals Reports First Quarter 2024 Financial Results and Provides Business Update
|
|
May 7
|
Mirum Pharmaceuticals to Present at the Citizens JMP Life Sciences Conference
|
|
May 7
|
Mirum Announces Publication of Phase 3 MARCH Data in The Lancet Demonstrating Benefits of LIVMARLI (maralixibat) in patients with PFIC
|
|
May 2
|
Stonegate Healthcare Partners Updates Report on Transformative Therapies for Pruritus Management
|
|
May 1
|
Mirum Pharmaceuticals to Announce First Quarter 2024 Financial Results and Host Conference Call on May 8, 2024
|
|
Apr 30
|
Halozyme Therapeutics (HALO) Earnings Expected to Grow: Should You Buy?
|
|
Apr 2
|
Mirum Pharmaceuticals’ LIVMARLI (maralixibat oral solution) Receives Positive Reimbursement Recommendation by Canada’s CADTH for Patients with Cholestatic Pruritus in Alagille Syndrome
|
|
Mar 29
|
Mirum Pharmaceuticals (MIRM) Down 12.5% Since Last Earnings Report: Can It Rebound?
|
|
Mar 26
|
Mirum Pharmaceuticals Inc (MIRM) Insider Sells Shares
|
|
Mar 25
|
Sagimet Biosciences Announces Appointment of Tim Walbert and Paul Hoelscher to its Board of Directors
|
|
Mar 15
|
Mirum's (MIRM) Livmarli Receives FDA Nod for Expanded Use
|
|
Mar 13
|
Mirum Pharmaceuticals’ LIVMARLI Receives FDA Approval for Treatment of Cholestatic Pruritus in Patients with Progressive Familial Intrahepatic Cholestasis
|
|
Jan 16
|
Mirum Pharmaceuticals Appoints Joanne Quan, MD as Chief Medical Officer
|
|
Jan 15
|
Should You Invest in Mirum Pharmaceuticals (MIRM)?
|